Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 20.504 mg (equivalent: galantamine, qty 16 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; titanium dioxide; microcrystalline cellulose; iron oxide red; magnesium stearate; hypromellose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: hypromellose; gelatin; magnesium stearate; microcrystalline cellulose; ethylcellulose; titanium dioxide - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

rebel distributors corp - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine hydrobromide 8 mg - razadyne® er/razadyne® (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the alzheimer's type. razadyne® er/razadyne® (galantamine hydrobromide) is contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation.

Armenia - Tiếng Anh - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmaten international s.a. industrial park sapes - galantamine (galantamine hydrobromide) - capsules prolonged-release, hard - 8mg

Armenia - Tiếng Anh - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmaten international s.a. industrial park sapes - galantamine (galantamine hydrobromide) - capsules prolonged-release, hard - 16mg

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 8 mg - razadyne er is indicated for the treatment of mild to moderate dementia of the alzheimer's type. razadyne er is contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of razadyne er or galantamine tablets in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data in rats, administration of galantamine (oral doses of 2, 8, or 16 mg/kg/da

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

actavis pharma, inc. - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 8 mg - galantamine extended-release capsules are indicated for the treatment of mild to moderate dementia of the alzheimer’s type. galantamine extended-release capsules are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of galantamine extended-release capsules in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically (see data) . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data in rats,

Canada - Tiếng Anh - Health Canada

marcan pharmaceuticals inc - galantamine (galantamine hydrobromide) - capsule (extended release) - 8mg - galantamine (galantamine hydrobromide) 8mg - parasympathomemetic (cholinergic) agents

Canada - Tiếng Anh - Health Canada

marcan pharmaceuticals inc - galantamine (galantamine hydrobromide) - capsule (extended release) - 16mg - galantamine (galantamine hydrobromide) 16mg - parasympathomemetic (cholinergic) agents

Canada - Tiếng Anh - Health Canada

marcan pharmaceuticals inc - galantamine (galantamine hydrobromide) - capsule (extended release) - 24mg - galantamine (galantamine hydrobromide) 24mg - parasympathomemetic (cholinergic) agents